{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:25:06Z","timestamp":1791923106037,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01833-3","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T08:53:05Z","timestamp":1786092785000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A phase 1 trial of CD123-directed chimeric antigen receptor T-cell therapy in adults with relapsed\/refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm"],"prefix":"10.1186","volume":"19","author":[{"given":"Lihua E.","family":"Budde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa M.","family":"Del Real","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Stiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Aribi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karamjeet","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela C.","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary C.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie R.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinny","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Suzette","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joycelynne","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"1833_CR1","doi-asserted-by":"publisher","unstructured":"Premnath N, Madanat YF. Paradigm Shift in the Management of Acute Myeloid Leukemia-Approved Options in 2023. Cancers (Basel). 2023;15(11):3002. https:\/\/doi.org\/10.3390\/cancers15113002","DOI":"10.3390\/cancers15113002"},{"issue":"8","key":"1833_CR2","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood-2010-10-265603","volume":"117","author":"V Gupta","year":"2011","unstructured":"Gupta V, Tallman MS, Weisdorf DJ. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood. 2011;117(8):2307\u201318.","journal-title":"Blood"},{"key":"1833_CR3","doi-asserted-by":"publisher","first-page":"608916","DOI":"10.3389\/fonc.2020.608916","volume":"10","author":"SR Goldsmith","year":"2020","unstructured":"Goldsmith SR, Ghobadi A, DiPersio JF. Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors? Front Oncol. 2020;10:608916.","journal-title":"Front Oncol"},{"issue":"6","key":"1833_CR4","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1182\/blood-2011-08-375840","volume":"119","author":"C Schmid","year":"2012","unstructured":"Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R, et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood. 2012;119(6):1599\u2013606.","journal-title":"Blood"},{"issue":"3","key":"1833_CR5","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","volume":"21","author":"N Bejanyan","year":"2015","unstructured":"Bejanyan N, Weisdorf DJ, Logan BR, Wang HL, Devine SM, de Lima M, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transpl. 2015;21(3):454\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1833_CR6","doi-asserted-by":"publisher","unstructured":"Daver N, Blachly JS, Ghobadi A, Advani A, Muffly L, Garciaz S et al. Phase 1 Study of KITE-222, an Autologous CLL-1-directed CAR T-cell Therapy in Patients With Relapsed\/Refractory Acute Myeloid Leukemia. Clin Cancer Res. 2026;32(13):2604\u20132613. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-3745","DOI":"10.1158\/1078-0432.CCR-25-3745"},{"issue":"6","key":"1833_CR7","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","volume":"173","author":"MY Kim","year":"2018","unstructured":"Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, et al. Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell. 2018;173(6):1439\u2013e5319.","journal-title":"Cell"},{"issue":"11","key":"1833_CR8","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","volume":"35","author":"FP Tambaro","year":"2021","unstructured":"Tambaro FP, Singh H, Jones E, Rytting M, Mahadeo KM, Thompson P, et al. Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia. Leukemia. 2021;35(11):3282\u20136.","journal-title":"Leukemia"},{"key":"1833_CR9","doi-asserted-by":"publisher","unstructured":"Qin H, Yang L, Chukinas JA, Shah N, Tarun S, Pouzolles M et al. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design. J Immunother Cancer. 2021;9(9):e003149. https:\/\/doi.org\/10.1136\/jitc-2021-003149corr1","DOI":"10.1136\/jitc-2021-003149corr1"},{"issue":"17","key":"1833_CR10","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1182\/blood.2025031053","volume":"147","author":"MU Mushtaq","year":"2026","unstructured":"Mushtaq MU, DiPersio JF, Azzi J, Cooper BW, Koehne G, Koura D, et al. A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT. Blood. 2026;147(17):1914\u201327.","journal-title":"Blood"},{"issue":"Supplement1","key":"1833_CR11","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1182\/blood-2019-128020","volume":"134","author":"DA Sallman","year":"2019","unstructured":"Sallman DA, Brayer JB, Poire X, Havelange V, Awada A, Lewalle P, et al. Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse\/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. Blood. 2019;134(Supplement1):3826.","journal-title":"Blood"},{"issue":"1","key":"1833_CR12","doi-asserted-by":"publisher","first-page":"ltab018","DOI":"10.1093\/immadv\/ltab018","volume":"1","author":"S Curio","year":"2021","unstructured":"Curio S, Jonsson G, Marinovi\u0107 S. A summary of current NKG2D-based CAR clinical trials. Immunother Adv. 2021;1(1):ltab018.","journal-title":"Immunother Adv"},{"key":"1833_CR13","doi-asserted-by":"publisher","unstructured":"Pollyea D, Kerre T, Deeren D, Beguin Y, Lin TL, Sallman DA et al. Downregulation of MICA\/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia. Leukemia. 2025;39(12):2907\u20132915. https:\/\/doi.org\/10.1038\/s41375-025-02767-4","DOI":"10.1038\/s41375-025-02767-4"},{"key":"1833_CR14","doi-asserted-by":"publisher","unstructured":"Geyer MB, DeWolf S, Mi X, Weis K, Shaffer BC, Cadzin B et al. CD371-Targeted CAR T cells Secreting Interleukin-18 Exhibit Robust Expansion and Clear Refractory Acute Myeloid Leukemia. Blood. 2025 ;146(26)3163\u20133174. https:\/\/doi.org\/10.1182\/blood.2025029532","DOI":"10.1182\/blood.2025029532"},{"issue":"1","key":"1833_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2050-7771-2-4","volume":"2","author":"U Testa","year":"2014","unstructured":"Testa U, Pelosi E, Frankel A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res. 2014;2(1):4.","journal-title":"Biomark Res"},{"issue":"5","key":"1833_CR16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/stem.160301","volume":"16","author":"MA Guthridge","year":"1998","unstructured":"Guthridge MA, Stomski FC, Thomas D, Woodcock JM, Bagley CJ, Berndt MC, et al. Mechanism of activation of the GM-CSF, IL-3, and IL-5 family of receptors. Stem Cells. 1998;16(5):301\u201313.","journal-title":"Stem Cells"},{"issue":"6","key":"1833_CR17","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/MOH.0000000000000190","volume":"22","author":"A Mardiros","year":"2015","unstructured":"Mardiros A, Forman SJ, Budde LE. T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Curr Opin Hematol. 2015;22(6):484\u20138.","journal-title":"Curr Opin Hematol"},{"issue":"6","key":"1833_CR18","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1182\/blood.2020007732","volume":"137","author":"GL Uy","year":"2021","unstructured":"Uy GL, Aldoss I, Foster MC, Sayre PH, Wieduwilt MJ, Advani AS, et al. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2021;137(6):751\u201362.","journal-title":"Blood"},{"issue":"12","key":"1833_CR19","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1080\/14712598.2025.2608209","volume":"25","author":"S Arslan","year":"2025","unstructured":"Arslan S, Aribi A, Stein A, Aldoss I. Current status and future potential of CD123-based targeted therapies for acute leukemia. Expert Opin Biol Ther. 2025;25(12):1299\u2013312.","journal-title":"Expert Opin Biol Ther"},{"issue":"18","key":"1833_CR20","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","volume":"122","author":"A Mardiros","year":"2013","unstructured":"Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013;122(18):3138\u201348.","journal-title":"Blood"},{"issue":"6","key":"1833_CR21","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/CJI.0b013e318053ed8e","volume":"30","author":"X Du","year":"2007","unstructured":"Du X, Ho M, Pastan I. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J Immunother. 2007;30(6):607\u201313.","journal-title":"J Immunother"},{"issue":"6","key":"1833_CR22","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.copbio.2009.10.011","volume":"20","author":"WR Strohl","year":"2009","unstructured":"Strohl WR. Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol. 2009;20(6):685\u201391.","journal-title":"Curr Opin Biotechnol"},{"issue":"5","key":"1833_CR23","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","volume":"118","author":"X Wang","year":"2011","unstructured":"Wang X, Chang WC, Wong CW, Colcher D, Sherman M, Ostberg JR, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood. 2011;118(5):1255\u201363.","journal-title":"Blood"},{"issue":"1","key":"1833_CR24","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.cct.2010.09.011","volume":"32","author":"MS Blanchard","year":"2011","unstructured":"Blanchard MS, Longmate JA. Toxicity equivalence range design (TEQR): a practical Phase I design. Contemp Clin Trials. 2011;32(1):114\u201321.","journal-title":"Contemp Clin Trials"},{"issue":"2","key":"1833_CR25","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188\u201395.","journal-title":"Blood"},{"issue":"24","key":"1833_CR26","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1833_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3324\/haematol.2012.072645","volume":"98","author":"L Pagano","year":"2013","unstructured":"Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98(2):239\u201346.","journal-title":"Haematologica"},{"issue":"1","key":"1833_CR28","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1002\/cpcy.73","volume":"93","author":"BL Wood","year":"2020","unstructured":"Wood BL. Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach. Curr Protocols Cytometry. 2020;93(1):e73.","journal-title":"Curr Protocols Cytometry"},{"issue":"24","key":"1833_CR29","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","volume":"127","author":"X Wang","year":"2016","unstructured":"Wang X, Popplewell LL, Wagner JR, Naranjo A, Blanchard MS, Mott MR, et al. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Blood. 2016;127(24):2980\u201390.","journal-title":"Blood"},{"issue":"12","key":"1833_CR30","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1038\/s41591-024-03271-5","volume":"30","author":"AS Bhagwat","year":"2024","unstructured":"Bhagwat AS, Torres L, Shestova O, Shestov M, Mellors PW, Fisher HR, et al. Cytokine-mediated CAR T therapy resistance in AML. Nat Med. 2024;30(12):3697\u2013708.","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"1833_CR31","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1182\/blood-2022-168877","volume":"140","author":"G Ehninger","year":"2022","unstructured":"Ehninger G, Kraus S, Sala E, Metzelder SK, Vucinic V, Fiedler W, et al. Phase 1 Dose Escalation Study of the Rapidly Switchable Universal CAR-T Therapy Unicar-T-CD123 in Relapsed\/Refractory AML. Blood. 2022;140(Supplement 1):2367\u20138.","journal-title":"Blood"},{"key":"1833_CR32","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1182\/blood-2024-208795","volume":"144","author":"S Naik","year":"2024","unstructured":"Naik S, Renee M, Talleur AC, Epperly R, Lockey T, Bran J, et al. CD123-CAR T Cells Manufactured in the Presence of Dasatinib Induce High Grade CRS and\/or IEC-HS without Improving Efficacy in Pediatric Patients with Recurrent\/Refractory Leukemia. Blood. 2024;144:2076.","journal-title":"Blood"},{"key":"1833_CR33","first-page":"1359","volume":"130","author":"KD Cummins","year":"2017","unstructured":"Cummins KD, Frey N, Nelson AM, Schmidt A, Luger S, Isaacs RE, et al. Treating Relapsed \/ Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells. Blood. 2017;130:1359.","journal-title":"Blood"},{"issue":"15","key":"1833_CR34","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","volume":"123","author":"S Gill","year":"2014","unstructured":"Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood. 2014;123(15):2343\u201354.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1833_CR35","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1182\/blood-2022-169928","volume":"140","author":"DA Sallman","year":"2022","unstructured":"Sallman DA, DeAngelo DJ, Pemmaraju N, Dinner S, Gill S, Olin RL, et al. Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R\/R) CD123\u2009+\u2009Acute Myeloid Leukemia (AML). Blood. 2022;140(Supplement 1):2371\u20133.","journal-title":"Blood"},{"key":"1833_CR36","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.2147\/OTT.S205678","volume":"12","author":"Y Sun","year":"2019","unstructured":"Sun Y, Wang S, Zhao L, Zhang B, Chen H. IFN-\u03b3 and TNF-\u03b1 aggravate endothelial damage caused by CD123-targeted CAR T cell. Onco Targets Ther. 2019;12:4907\u201325.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"1833_CR37","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, Diaz-Beya M, Juan M, et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target Ther. 2025;10(1):210.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"1833_CR38","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood.2024024063","volume":"145","author":"S Haubner","year":"2025","unstructured":"Haubner S, Subklewe M, Sadelain M. Honing CAR T cells to tackle acute myeloid leukemia. Blood. 2025;145(11):1113\u201325.","journal-title":"Blood"},{"issue":"10","key":"1833_CR39","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1182\/blood.2020007897","volume":"137","author":"W Xiao","year":"2021","unstructured":"Xiao W, Chan A, Waarts MR, Mishra T, Liu Y, Cai SF, et al. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia. Blood. 2021;137(10):1377\u201391.","journal-title":"Blood"},{"issue":"4","key":"1833_CR40","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1111\/bjh.70043","volume":"207","author":"RS Azevedo","year":"2025","unstructured":"Azevedo RS, Wang SA, Swanson DM, Daver NG, Pemmaraju N, Kadia TM, et al. CD123 expression and its correlation with mutation profile in acute myeloid leukaemia. Br J Haematol. 2025;207(4):1648\u201352.","journal-title":"Br J Haematol"},{"issue":"3","key":"1833_CR41","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","volume":"10","author":"DA Sallman","year":"2023","unstructured":"Sallman DA, Kerre T, Havelange V, Poir\u00e9 X, Lewalle P, Wang ES, et al. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. Lancet Haematol. 2023;10(3):e191\u2013202.","journal-title":"Lancet Haematol"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01833-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01833-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01833-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:07:07Z","timestamp":1788275227000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01833-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1833"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01833-3","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The clinical study was approved by the City of Hope Institutional Review Board (IRB #13272) and conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization (ICH) Guideline for Good Clinical Practice (ICH E6).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"68"}}